about
LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1Expression and structural characterization of the recombinant human doppel proteinParadoxical role of prion protein aggregates in redox-iron induced toxicity.Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's diseaseLRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's diseaseCharacterization of the prion protein in human urine.Sporadic and familial CJD: classification and characterisation.Regulation of DJ-1 by Glutaredoxin 1 in Vivo: Implications for Parkinson's Disease.CD3 in Lewy pathology: does the abnormal recall of neurodevelopmental processes underlie Parkinson's disease.Glutaredoxin deficiency exacerbates neurodegeneration in C. elegans models of Parkinson's disease.Creutzfeldt-Jakob disease (CJD) with a mutation at codon 148 of prion protein gene: relationship with sporadic CJD.Hereditary Creutzfeldt-Jakob disease and fatal familial insomnia.LRRK2 in Parkinson's disease and dementia with Lewy bodies.Chronic wasting disease of elk and deer and Creutzfeldt-Jakob disease: comparative analysis of the scrapie prion proteinInducible overexpression of wild-type prion protein in the muscles leads to a primary myopathy in transgenic mice.Is nitric oxide a key target in the pathogenesis of brain lesions during the development of Alzheimer's disease?Assessing prion infectivity of human urine in sporadic Creutzfeldt-Jakob diseaseAntibody to DNA detects scrapie but not normal prion protein.The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activityDifferent patterns of truncated prion protein fragments correlate with distinct phenotypes in P102L Gerstmann-Sträussler-Scheinker disease.Leucine-rich repeat kinase 2: relevance to Parkinson's disease.Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicityThe Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubulesLeucine-rich repeat kinase 2 colocalizes with alpha-synuclein in Parkinson's disease, but not tau-containing deposits in tauopathies.Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson's diseaseExposure to the Functional Bacterial Amyloid Protein Curli Enhances Alpha-Synuclein Aggregation in Aged Fischer 344 Rats and Caenorhabditis elegans.Cryptic peptides of the kringle domains preferentially bind to disease-associated prion protein.Genetic influence on the structural variations of the abnormal prion protein.Neuronal mitochondrial amelioration by feeding acetyl-L-carnitine and lipoic acid to aged rats.Fatal familial insomnia and familial Creutzfeldt-Jakob disease: clinical, pathological and molecular features.Prion protein functions as a ferrireductase partner for ZIP14 and DMT1.Absence of protease-resistant prion protein in the cerebrospinal fluid of Creutzfeldt-Jakob disease.Novel differences between two human prion strains revealed by two-dimensional gel electrophoresis.Identification of novel proteinase K-resistant C-terminal fragments of PrP in Creutzfeldt-Jakob disease.Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta.Protease-resistant human prion protein and ferritin are cotransported across Caco-2 epithelial cells: implications for species barrier in prion uptake from the intestine.Tau gene mutation in familial progressive subcortical gliosis.Gerstmann-Sträussler-Scheinker: a new phenotype with 'curly' PrP deposits.Typing prion isoforms.Regional distribution of protease-resistant prion protein in fatal familial insomnia.
P50
Q24301357-CE9D23E7-608C-46DC-B0A8-7E4CB47230FDQ28143039-C2CAC4BB-2AE8-4D48-BDEE-DE4981F3AB2BQ33631161-EF7F2250-98DA-4D91-864C-2547F3AE6648Q33812599-C03A042E-4449-4A74-B8BB-0667AE651FE0Q34079774-9E75C7DB-BDC0-43FC-9DB4-8B1043FAFF55Q34155264-DBDF7480-71B4-47F7-BB7C-05BD8966C13DQ34266916-E279D097-9C8B-4186-9A56-362A9C4F1DC6Q34514815-176E75F4-07DB-4028-8637-F8D99C636B10Q34953854-48941EC6-F594-4715-B29E-7D7E4F175EA6Q35063145-69098A4A-425A-460D-A2F4-6537812A107CQ35094470-A6D64241-3436-4FEE-99DC-DF8AC9DC894AQ35122319-99A1513D-A8C1-4056-B89E-8A5B17F59BBBQ35214380-2520A380-A5DE-4BED-B822-DF7B2BFB445BQ35794889-89795AF9-29C2-43A2-A401-038B8FBC69A1Q35800381-C7268B02-297F-4FE0-94E7-84FEE3727511Q35841713-6F29E035-9A22-4386-9C73-FEE294AE9BEFQ35845872-916B0B64-DA8E-46A2-AA4E-EAAC79674393Q36018267-46965CD7-CF72-41FB-962F-5BFFA2760DB4Q36154267-AF8505C0-19D3-4FCB-A792-3A5A5A80E7E2Q36174780-B9A19297-B22D-411A-BCB5-B607BA9C8F3AQ36442827-BA7A8C4F-4A69-4B30-8DF2-2F0BE8AF42A9Q36477677-E6A53881-631F-4FEA-978F-61E56A5EF6D3Q36982616-3789F531-1072-4248-B52B-9E444F371E52Q37181158-2CE0973C-F050-45E2-930A-6F8F42DB3017Q37295370-690B9580-B529-4098-BC3F-B3B2D8938DBDQ37315005-5E97761E-514D-4E17-B184-CD6943D1D821Q37340572-954D2EF0-D4F0-470C-8F4B-48190AFBC287Q37422460-D9124A85-2F28-4CBD-8EDE-5789927283A8Q37465606-50FC746C-7302-4DD1-BA64-3ECC594302B0Q40537014-F3E7819C-2365-49CD-9ECC-DD34A62E84E1Q41829749-6D8F19DA-77E1-4931-88E8-69BE9D3011CCQ43592525-C53788E0-E857-4778-A8D3-5BA5BB88D927Q43699016-F352BE7C-B457-4855-B0A8-41DB41C9EA31Q44548848-F119D43F-AC7B-4569-92F7-41D7B3849181Q44724513-B96C4FAE-1895-4693-96F3-9F68D4B635D9Q45188909-68A8D115-2B02-461B-BF11-AD7886986E6CQ48236600-9B3EB361-09B9-42BB-8727-4B4244C9F823Q48476968-FDDAC932-1E37-47B6-8D9A-FC1E40B8F89DQ48762703-740E1502-7432-4F97-9BDE-EAEB26948CB6Q48811338-0443AB88-0466-4BA4-953D-B6C20260AF3E
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Shu Chen
@ast
Shu Chen
@en
Shu Chen
@es
Shu Chen
@nl
Shu Chen
@sl
type
label
Shu Chen
@ast
Shu Chen
@en
Shu Chen
@es
Shu Chen
@nl
Shu Chen
@sl
prefLabel
Shu Chen
@ast
Shu Chen
@en
Shu Chen
@es
Shu Chen
@nl
Shu Chen
@sl
P1053
O-4750-2014
P106
P21
P31
P3829
P496
0000-0001-7180-3001